Security key
68236X100
Starling Oncology, Inc. - Common Stock, par value $0.0001 per share (TOI)
CUSIP: 68236X100
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 40,090,586
- Total 13F value
- $217,590,724
- Share change
- +1,374,754
- Put/Call ratio
- 7.6%
- SEC-reported price per share
- $5.43
- Number of holders
- 119
- Value change
- +$22,311,550
- Number of buys
- 77
- Number of sells
- 43
- Shares outstanding
- 101,268,340
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
119
Top holders
10
TOI full security history
Ownership snapshot
Full 13F holder table
Oncology Institute, Inc. SEC filings
Oncology Institute, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of TOI - Starling Oncology, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Jorey Chernett
Disclosed value leader
Jorey Chernett
Comparable rows
15/15
Latest evidence
21 Apr 2026
13D/G
3/4/5
13F
Lead comparable stake: 10%
13D/G row: Jorey Chernett
Showing 1-6 of 15 holder rows.
Quick read
Jorey Chernett leads the comparable SEC ownership view at 10%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Jorey Chernett's linked filing trail.
Comparable ownership
Top 5
Jorey Chernett
10%
M33 Growth I L.P.
4.9%
Ravi Yang Sarin
4.7%
Richard A. Barasch
2.6%
Gabriel Ling
0.33%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Jorey Chernett |
13D/G
Chernett Jorey
|
10%
|
$27,110,730
10,115,944 shares
|
$0 | 13 Mar 2026 |
| M33 Growth I L.P. |
3/4/5
13D/G
Director
|
4.9%
from 13D/G
|
$25,267,600
6,802,656 shares
mixed-class rows
|
-$20,703,000 | 18 Nov 2025 |
| Ravi Yang Sarin |
13D/G
3/4/5
Ravi Sarin · Director
|
4.7%
|
$11,959,434
4,109,771 shares
|
$0 | 26 Mar 2025 |
| Richard A. Barasch |
3/4/5
Director
|
2.6%
|
$5,488,459
2,635,881 shares
mixed-class rows
|
— | 12 Aug 2025 |
| Gabriel Ling |
3/4/5
Director
|
0.33%
|
$1,537,614
333,539 shares
|
— | 01 Dec 2025 |
| Kristin England |
3/4/5
Chief Administrative Officer
|
0.15%
|
$547,456
153,780 shares
|
— | 21 Apr 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
119
Shares
40,090,586
Rows available
119
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
115
Q2 2026 holders
119
Holder diff
4
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|